|
Revolutionizing the R/R DLBCL Treatment Paradigm: Innovative, Strategic & Targeted Approaches |
Oncology Learning Network |
CME, CNE, CPE |
Oncology |
On-Demand Webcast |
|
New and Emerging Agents in MCL |
Oncology Learning Network |
CME, CNE, CPE |
Oncology |
On-Demand Webcast |
|
New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies |
Oncology Learning Network |
CME, CNE, CPE |
Oncology |
On-Demand Webcast |
|
First- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy |
Oncology Learning Network |
CME, CNE, CPE |
Oncology |
On-Demand Webcast |
|
Positioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease |
Oncology Learning Network |
CME, CNE, CPE |
Oncology |
On-Demand Webcast |
|
Understanding Waldenström's Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies |
Oncology Learning Network |
CME, CNE, CPE |
Oncology |
On-Demand Webcast |
|
New and Emerging Agents in HCL |
Oncology Learning Network |
CME, CNE, CPE |
Oncology |
On-Demand Webcast |
|
Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors |
Oncology Learning Network |
CME, CNE, CPE |
Oncology |
On-Demand Webcast |
|
Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma |
Oncology Learning Network |
CME, CNE, CPE |
Oncology |
On-Demand Webcast |
|
Treatment for Marginal Zone Lymphoma: Should it be Different from FL? |
Oncology Learning Network |
CME, CNE, CPE |
Oncology |
On-Demand Webcast |
|
Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges |
Oncology Learning Network |
CME, CNE, CPE |
Oncology |
On-Demand Webcast |
|
Recent Advances in Acute Leukemia Management |
Oncology Learning Network |
CME, CNE, CPE |
Oncology |
On-Demand Webcast |
